Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. Leveraging a small-molecule and biologics platform, the firm designs therapies that modulate the tumor microenvironment and enhance the immune system’s ability to target and destroy cancer cells. Its core research areas include adenosine pathway inhibitors and immune checkpoint modulators, which are intended to work alone or in combination with other immuno-oncology agents.
The company’s lead candidates include a dual A2a/A2b adenosine receptor antagonist and monoclonal antibodies targeting PD-1 and TIGIT. These investigational medicines are being evaluated across multiple tumor types, including non-small cell lung cancer, colorectal cancer and other solid tumors. In addition to its internal pipeline, Arcus has established strategic collaborations to support the development and commercialization of select assets, thereby expanding its reach and accelerating clinical progress.
Founded in 2015 as a University of California, Berkeley spin-out, Arcus completed its initial public offering in 2020 and is headquartered in San Diego, California. From its West Coast base, the company conducts research and clinical operations in North America, Asia and Europe, reflecting a commitment to global patient populations. Over the years, Arcus has built a diversified portfolio of preclinical and clinical programs rooted in a deep understanding of tumor immunology and drug discovery.
Under the leadership of President and Chief Executive Officer Pablo Cagnoni, Arcus Biosciences has assembled a management team with extensive experience in biopharmaceutical innovation, clinical development and regulatory affairs. The company’s board and scientific advisory panels include experts in oncology research, ensuring robust oversight of its translational science and clinical strategy. This leadership structure supports Arcus’s goal of delivering novel immunotherapies to patients with high unmet medical needs.
